People Background Check
Find People:

Keith Hornberger, Age 491554 Jacksonville Rd, Burlington, NJ 08016

Get Report
Related to:
Valorie J Steinmetz 64 Hornberger K Steinmetz Kelle H Cox 58 Gwen Jackson 49 Barry R Steinmetz 67

Keith Hornberger Phones & Addresses

1554 Jacksonville Rd, Burlington, NJ 08016

Work

Position: Craftsman/Blue Collar

Education

Degree: High school graduate or higher

Mentions for Keith Hornberger

Keith Hornberger resumes & CV records

Resumes

Keith Hornberger Photo 15

Keith Hornberger

Keith Hornberger Photo 16

Principal Scientist At Boehringer Ingelheim Pharmaceuticals

Position:
Principal Scientist at Boehringer Ingelheim
Location:
Ridgefield, Connecticut
Industry:
Pharmaceuticals
Work:
Boehringer Ingelheim since Apr 2013
Principal Scientist OSI Pharmaceuticals - Farmingdale, NY Dec 2011 - Apr 2013
Senior Research Investigator, Cancer Chemistry OSI Pharmaceuticals Nov 2008 - Dec 2011
Research Investigator, Cancer Chemistry GlaxoSmithKline Aug 2002 - Oct 2008
Investigator - Oncology Medicinal Chemistry
Education:
Columbia University in the City of New York 1997 - 2002
Ph.D., Chemistry University of Delaware 1993 - 1997
B.S., Chemistry
Skills:
Medicinal Chemistry

Publications & IP owners

Us Patents

Tetrahydronaphthalene And Tetrahydroisoquinoline Derivatives As Estrogen Receptor Degraders

US Patent:
2021013, May 13, 2021
Filed:
Jun 1, 2020
Appl. No.:
16/889490
Inventors:
- New Haven CT, US
Yimin Qian - Plainsboro NJ, US
Hanqing Dong - Madison CT, US
Jing Wang - Milford CT, US
Keith R. Hornberger - Southbury CT, US
Craig M. Crews - New Haven CT, US
International Classification:
C07D 401/14
A61K 31/4545
A61K 38/06
C07D 487/08
C07D 487/04
A61P 35/00
A61K 31/5386
A61K 38/05
C07K 5/083
A61K 31/497
A61K 47/54
C07D 498/10
A61K 45/06
A61K 31/454
C07K 5/078
C07D 487/10
C07D 401/04
A61K 31/501
A61K 31/519
A61K 31/4725
C07D 471/04
C07D 471/10
A61K 31/496
A61P 15/00
A61K 31/551
Abstract:
The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Tetrahydronaphthalene And Tetrahydroisoquinoline Derivatives As Estrogen Receptor Degraders

US Patent:
2018015, Jun 7, 2018
Filed:
Dec 1, 2017
Appl. No.:
15/829541
Inventors:
- New Haven CT, US
Yimin Qian - Plainsboro NJ, US
Hanqing Dong - Madison CT, US
Jing Wang - Milford CT, US
Keith R. Hornberger - Southbury CT, US
Craig M. Crews - New Haven CT, US
International Classification:
C07D 401/14
C07K 5/083
A61K 38/06
C07D 401/04
C07D 487/08
A61K 31/4725
A61K 31/454
C07D 487/10
A61K 31/4545
A61K 31/551
A61K 31/497
C07D 498/10
A61K 31/5386
A61K 31/501
C07D 471/04
C07D 471/10
C07D 487/04
A61K 31/519
A61K 45/06
A61K 31/496
C07K 5/078
A61K 38/05
A61P 35/00
A61P 15/00
Abstract:
The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Possible Relatives

Debbie F Hornberger  Ellen J Hornberger  George V Hornberger  Jack C Hornberger  Jacob D Hornberger  Karl M Hornberger  Lori L Hornberger  Keith E Johnston  Keith W Stanfield  Keith K Stanley 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.